- On the evening of May 13th, Shengnuo Biotech disclosed its prospectus of intent
- The pharmaceutical research of peptide innovative drugs and the production services of peptide customized products that Shengnuo Biotech is engaged in are a subdivision of CDMO (Contract Research and Development and Production Organization) services. It is a CDMO service specifically for peptide innovative drugs.
On the evening of May 13th, Shengnuo Biotech disclosed its prospectus of intent
. This time it plans to publicly issue 20 million RMB ordinary shares, and the raised funds will be invested in the production line project of 395 kg of peptide APIs, the technological transformation project of preparation industrialization and the upgrading project of the engineering technology center.
Shengnuo Biotech is a high-tech enterprise with core peptide synthesis and modification technologies, with advanced and efficient peptide drug technology research and development and large-scale production capabilities. The company’s main business is independent research and development, production and sales of peptide APIs and preparation products with large market capacity and strong competitiveness at home and abroad. At the same time, the company relies on its technological advantages in the field of peptide drug research and development and large-scale production.
Foreign pharmaceutical companies provide pharmaceutical research services for innovative peptide drugs, customized production services for peptide products, and technology transfer services for peptide drug production. In addition, the company also provides small-molecule chemical drug levosimendan preparations on behalf of processing and levosimendan bulk drug production, export sales business.
The pharmaceutical research of peptide innovative drugs and the production services of peptide customized products that Shengnuo Biotech is engaged in are a subdivision of CDMO (Contract Research and Development and Production Organization) services. It is a CDMO service specifically for peptide innovative drugs.
The company selects peptide generic drugs with large market capacity and strong market competitiveness at home and abroad for research and development, and has mastered the large-scale production technology of 15 varieties of APIs, of which 7 varieties have obtained production approvals and 8 varieties in China Obtained the US DMF registration (activated status), and the extended development of 8 peptide preparations has obtained 12 domestic production approvals.
The products cover immune system diseases, tumors, cardiovascular, chronic hepatitis B, diabetes and obstetric diseases and other peptide drugs play an important role field of.
From 2018 to 2020, Shengnuo Biotech will achieve operating income of 278 million yuan, 327 million yuan, and 379 million yuan, respectively, and realize the net profit attributable to the owners of the parent company of 29,861,300 yuan, 48,131,700 yuan and 59,997,800 yuan.
From January to March 2021, the company achieved operating income of RMB 93.2802 million, a year-on-year increase of 30.47%; realized net profit attributable to owners of the parent company of RMB 11.654 million, a year-on-year increase of 37.12%; realized deduction of non-recurring gains and losses attributable to the parent company The owner’s net profit was 11.825 million yuan, a year-on-year increase of 44.73%.
Looking forward to the future, the company said that it will seize the rapid growth of the peptide generic drug market, continue to deepen the peptide drug market, continue to improve process technology, research and development strength, marketing management, channel construction and comprehensive management capabilities, and improve overall competitiveness and profitability.
Level, grasp the development trend of the global pharmaceutical industry, take the pharmaceutical research service of peptide innovative drugs, customized production service of peptide products, and peptide API products as starting points, actively integrate into the domestic and foreign pharmaceutical industry chain, and extend the development of more peptide preparation varieties , To further increase the promotion of preparations and the promotion and management level.
At the same time, the company will actively deploy the peptide innovative drug business field through cooperative research and development, and consolidate the company’s competitive position in the industry.